{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T22:56:51Z","timestamp":1754261811095},"reference-count":60,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,17]]},"DOI":"10.7759\/cureus.35109","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T19:07:31Z","timestamp":1676660851000},"source":"Crossref","is-referenced-by-count":3,"title":["A Pharmacological Review of Calcitonin Gene-Related Peptide Biologics and Future Use for Chronic Pain"],"prefix":"10.7759","author":[{"given":"David","family":"Cooper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D","family":"Laidig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Sappington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"MacGregor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2017.01.012","article-title":"Adverse reactions to biologic therapy","volume":"37","author":"Patel SV","year":"2017","unstructured":"Patel SV, Khan DA. Adverse reactions to biologic therapy. Immunol Allergy Clin North Am. 2017, 37:397-412. 10.1016\/j.iac.2017.01.012","journal-title":"Immunol Allergy Clin North Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13930","article-title":"Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine","volume":"60","author":"Berman G","year":"2020","unstructured":"Berman G, Croop R, Kudrow D, et al.. Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine. Headache. 2020, 60:1734-42. 10.1111\/head.13930","journal-title":"Headache"},{"key":"ref3","article-title":"Migraine overview and summary of current and emerging treatment options","volume":"25","author":"Peters GL","year":"2019","unstructured":"Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019, 25:S23-34.","journal-title":"Am J Manag Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0807-1","article-title":"Blocking CGRP in migraine patients - a review of pros and cons","volume":"18","author":"Deen M","year":"2017","unstructured":"Deen M, Correnti E, Kamm K, et al.. Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017, 18:96. 10.1186\/s10194-017-0807-1","journal-title":"J Headache Pain"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00834-9","article-title":"Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysis","volume":"35","author":"Overeem LH","year":"2021","unstructured":"Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U. Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysis. CNS Drugs. 2021, 35:805-20. 10.1007\/s40263-021-00834-9","journal-title":"CNS Drugs"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000831","article-title":"The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine","volume":"158","author":"Iyengar S","year":"2017","unstructured":"Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain. 2017, 158:543-59. 10.1097\/j.pain.0000000000000831","journal-title":"Pain"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.03.031","article-title":"Independent roles of CGRP in cardioprotection and hemodynamic regulation in ischemic postconditioning","volume":"828","author":"Guo Z","year":"2018","unstructured":"Guo Z, Liu N, Chen L, Zhao X, Li MR. Independent roles of CGRP in cardioprotection and hemodynamic regulation in ischemic postconditioning. Eur J Pharmacol. 2018, 828:18-25. 10.1016\/j.ejphar.2018.03.031","journal-title":"Eur J Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2020.10.005","article-title":"CGRP receptor antagonism in COVID-19: potential cardiopulmonary adverse effects","volume":"27","author":"Skaria T","year":"2021","unstructured":"Skaria T, W\u00e4lchli T, Vogel J. CGRP receptor antagonism in COVID-19: potential cardiopulmonary adverse effects. Trends Mol Med. 2021, 27:7-10. 10.1016\/j.molmed.2020.10.005","journal-title":"Trends Mol Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-199377020-00026","article-title":"Preemptive analgesia--treating postoperative pain by preventing the establishment of central sensitization","volume":"77","author":"Woolf CJ","year":"1993","unstructured":"Woolf CJ, Chong MS. Preemptive analgesia--treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg. 1993, 77:362-79. 10.1213\/00000539-199377020-00026","journal-title":"Anesth Analg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2015.08.012","article-title":"Multimodal treatment of chronic pain","volume":"100","author":"Dale R","year":"2016","unstructured":"Dale R, Stacey B. Multimodal treatment of chronic pain. Med Clin North Am. 2016, 100:55-64. 10.1016\/j.mcna.2015.08.012","journal-title":"Med Clin North Am"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpa.2020.06.007","article-title":"An evidence-based review of CGRP mechanisms in the propagation of chronic visceral pain","volume":"34","author":"Urits I","year":"2020","unstructured":"Urits I, Li N, Bahrun E, et al.. An evidence-based review of CGRP mechanisms in the propagation of chronic visceral pain. Best Pract Res Clin Anaesthesiol. 2020, 34:507-16. 10.1016\/j.bpa.2020.06.007","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities","volume":"26","author":"Volkow ND","year":"2021","unstructured":"Volkow ND, Blanco C. The changing opioid crisis: development, challenges and opportunities. Mol Psychiatry. 2021, 26:218-33. 10.1038\/s41380-020-0661-4","journal-title":"Mol Psychiatry"},{"key":"ref13","article-title":"Pathophysiology of chronic pain","volume":"1","author":"Berger JM","year":"2016","unstructured":"Berger JM, Zelman V. Pathophysiology of chronic pain. Pain Med J. 2016, 1:30-49.","journal-title":"Pain Med J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-016-3481-8","article-title":"An overview of treatment approaches for chronic pain management","volume":"37","author":"Hylands-White N","year":"2017","unstructured":"Hylands-White N, Duarte RV, Raphael JH. An overview of treatment approaches for chronic pain management. Rheumatol Int. 2017, 37:29-42. 10.1007\/s00296-016-3481-8","journal-title":"Rheumatol Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00660-0","article-title":"Opioid-induced tolerance and hyperalgesia","volume":"33","author":"Mercadante S","year":"2019","unstructured":"Mercadante S, Arcuri E, Santoni A. Opioid-induced tolerance and hyperalgesia. CNS Drugs. 2019, 33:943-55. 10.1007\/s40263-019-00660-0","journal-title":"CNS Drugs"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199505000-00018","article-title":"The effect of intrinsic efficacy on opioid tolerance","volume":"82","author":"Duttaroy A","year":"1995","unstructured":"Duttaroy A, Yoburn BC. The effect of intrinsic efficacy on opioid tolerance. Anesthesiology. 1995, 82:1226-36. 10.1097\/00000542-199505000-00018","journal-title":"Anesthesiology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2016.08.002","article-title":"Allostatic mechanisms of opioid tolerance beyond desensitization and downregulation","volume":"37","author":"Cahill CM","year":"2016","unstructured":"Cahill CM, Walwyn W, Taylor AM, Pradhan AA, Evans CJ. Allostatic mechanisms of opioid tolerance beyond desensitization and downregulation. Trends Pharmacol Sci. 2016, 37:963-76. 10.1016\/j.tips.2016.08.002","journal-title":"Trends Pharmacol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid abuse in chronic pain--misconceptions and mitigation strategies","volume":"374","author":"Volkow ND","year":"2016","unstructured":"Volkow ND, McLellan AT. Opioid abuse in chronic pain--misconceptions and mitigation strategies. N Engl J Med. 2016, 374:1253-63. 10.1056\/NEJMra1507771","journal-title":"N Engl J Med"},{"key":"ref19","article-title":"A comprehensive review of opioid-induced hyperalgesia","volume":"14","author":"Lee M","year":"2011","unstructured":"Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011, 14:145-61.","journal-title":"Pain Physician"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2010.00962.x","article-title":"Associations between heat pain perception and opioid dose among patients with chronic pain undergoing opioid tapering","volume":"11","author":"Hooten WM","year":"2010","unstructured":"Hooten WM, Mantilla CB, Sandroni P, Townsend CO. Associations between heat pain perception and opioid dose among patients with chronic pain undergoing opioid tapering. Pain Med. 2010, 11:1587-98. 10.1111\/j.1526-4637.2010.00962.x","journal-title":"Pain Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/298240a0","article-title":"Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products","volume":"298","author":"Amara SG","year":"1982","unstructured":"Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 1982, 298:240-4. 10.1038\/298240a0","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1124\/pr.54.2.233","article-title":"International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors","volume":"54","author":"Poyner DR","year":"2002","unstructured":"Poyner DR, Sexton PM, Marshall I, et al.. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002, 54:233-46. 10.1124\/pr.54.2.233","journal-title":"Pharmacol Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1210\/en.2005-0918","article-title":"Calcitonin gene-related peptide receptor activation by receptor activity-modifying protein-1 gene transfer to vascular smooth muscle cells","volume":"147","author":"Zhang Z","year":"2006","unstructured":"Zhang Z, Dickerson IM, Russo AF. Calcitonin gene-related peptide receptor activation by receptor activity-modifying protein-1 gene transfer to vascular smooth muscle cells. Endocrinology. 2006, 147:1932-40. 10.1210\/en.2005-0918","journal-title":"Endocrinology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0741-2","article-title":"Calcitonin gene-related peptide and pain: a systematic review","volume":"18","author":"Schou WS","year":"2017","unstructured":"Schou WS, Ashina S, Amin FM, Goadsby PJ, Ashina M. Calcitonin gene-related peptide and pain: a systematic review. J Headache Pain. 2017, 18:34. 10.1186\/s10194-017-0741-2","journal-title":"J Headache Pain"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010814-124701","article-title":"Calcitonin gene-related peptide (CGRP): a new target for migraine","volume":"55","author":"Russo AF","year":"2015","unstructured":"Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015, 55:533-52. 10.1146\/annurev-pharmtox-010814-124701","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.04-12-03101.1984","article-title":"Calcitonin gene-related peptide immunoreactivity in the spinal cord of man and of eight other species","volume":"4","author":"Gibson SJ","year":"1984","unstructured":"Gibson SJ, Polak JM, Bloom SR, et al.. Calcitonin gene-related peptide immunoreactivity in the spinal cord of man and of eight other species. J Neurosci. 1984, 4:3101-11. 10.1523\/JNEUROSCI.04-12-03101.1984","journal-title":"J Neurosci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2005.03.031","article-title":"The spinal basis of opioid tolerance and physical dependence: Involvement of calcitonin gene-related peptide, substance P, and arachidonic acid-derived metabolites","volume":"26","author":"Trang T","year":"2005","unstructured":"Trang T, Quirion R, Jhamandas K. The spinal basis of opioid tolerance and physical dependence: Involvement of calcitonin gene-related peptide, substance P, and arachidonic acid-derived metabolites. Peptides. 2005, 26:1346-55. 10.1016\/j.peptides.2005.03.031","journal-title":"Peptides"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(87)90074-6","article-title":"Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats","volume":"403","author":"Oku R","year":"1987","unstructured":"Oku R, Satoh M, Fujii N, Otaka A, Yajima H, Takagi H. Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res. 1987, 403:350-4. 10.1016\/0006-8993(87)90074-6","journal-title":"Brain Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/117.3.427","article-title":"Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies","volume":"117 ( Pt 3)","author":"Goadsby PJ","year":"1994","unstructured":"Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain. 1994, 117 ( Pt 3):427-34. 10.1093\/brain\/117.3.427","journal-title":"Brain"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.09.028","article-title":"Cellular and molecular mechanisms of pain","volume":"139","author":"Basbaum AI","year":"2009","unstructured":"Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009, 139:267-84. 10.1016\/j.cell.2009.09.028","journal-title":"Cell"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2009.06.012","article-title":"Central sensitization: a generator of pain hypersensitivity by central neural plasticity","volume":"10","author":"Latremoliere A","year":"2009","unstructured":"Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009, 10:895-926. 10.1016\/j.jpain.2009.06.012","journal-title":"J Pain"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-12-05031.2003","article-title":"A conditional deletion of the NR1 subunit of the NMDA receptor in adult spinal cord dorsal horn reduces NMDA currents and injury-induced pain","volume":"23","author":"South SM","year":"2003","unstructured":"South SM, Kohno T, Kaspar BK, et al.. A conditional deletion of the NR1 subunit of the NMDA receptor in adult spinal cord dorsal horn reduces NMDA currents and injury-induced pain. J Neurosci. 2003, 23:5031-40. 10.1523\/JNEUROSCI.23-12-05031.2003","journal-title":"J Neurosci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704682","article-title":"BIBN4096BS is a potent competitive antagonist of the relaxant effects of \u03b1-CGRP on human temporal artery: comparison with CGRP(8-37)","volume":"136","author":"Verheggen R","year":"2002","unstructured":"Verheggen R, Bumann K, Kaumann AJ. BIBN4096BS is a potent competitive antagonist of the relaxant effects of \u03b1-CGRP on human temporal artery: comparison with CGRP(8-37). Br J Pharmacol. 2002, 136:120-6. 10.1038\/sj.bjp.0704682","journal-title":"Br J Pharmacol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.165993","article-title":"Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries","volume":"334","author":"Chan KY","year":"2010","unstructured":"Chan KY, Edvinsson L, Eftekhari S, et al.. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther. 2010, 334:746-52. 10.1124\/jpet.110.165993","journal-title":"J Pharmacol Exp Ther"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.09.018","article-title":"Effects of the prototype serotonin 5-HT(1B\/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs","volume":"623","author":"Lynch JJ","year":"2009","unstructured":"Lynch JJ, Shen YT, Pittman TJ, et al.. Effects of the prototype serotonin 5-HT(1B\/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs. Eur J Pharmacol. 2009, 623:96-102. 10.1016\/j.ejphar.2009.09.018","journal-title":"Eur J Pharmacol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03869.x","article-title":"The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men","volume":"71","author":"Van der Schueren BJ","year":"2011","unstructured":"Van der Schueren BJ, Blanchard R, Murphy MG, et al.. The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men. Br J Clin Pharmacol. 2011, 71:708-17. 10.1111\/j.1365-2125.2010.03869.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.246","article-title":"A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina","volume":"91","author":"Chaitman BR","year":"2012","unstructured":"Chaitman BR, Ho AP, Behm MO, et al.. A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina. Clin Pharmacol Ther. 2012, 91:459-66. 10.1038\/clpt.2011.246","journal-title":"Clin Pharmacol Ther"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1981.tb12804.x","article-title":"Patterns of narcotic drug use in a cancer pain clinic","volume":"362","author":"Kanner RM","year":"1981","unstructured":"Kanner RM, Foley KM. Patterns of narcotic drug use in a cancer pain clinic. Ann N Y Acad Sci. 1981, 362:161-72. 10.1111\/j.1749-6632.1981.tb12804.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(91)90024-p","article-title":"Facilitatory role of calcitonin gene-related peptide (CGRP) on excitation induced by substance P (SP) and noxious stimuli in rat spinal dorsal horn neurons. An iontophoretic study in vivo","volume":"559","author":"Biella G","year":"1991","unstructured":"Biella G, Panara C, Pecile A, Sotgiu ML. Facilitatory role of calcitonin gene-related peptide (CGRP) on excitation induced by substance P (SP) and noxious stimuli in rat spinal dorsal horn neurons. An iontophoretic study in vivo. Brain Res. 1991, 559:352-6. 10.1016\/0006-8993(91)90024-p","journal-title":"Brain Res"},{"key":"ref40","article-title":"Tolerance to the antinociceptive properties of morphine in the rat spinal cord: alteration of calcitonin gene-related peptide-like immunostaining and receptor binding sites","volume":"273","author":"M\u00e9nard DP","year":"1995","unstructured":"M\u00e9nard DP, van Rossum D, Kar S, Jolicoeur FB, Jhamandas K, Quirion R. Tolerance to the antinociceptive properties of morphine in the rat spinal cord: alteration of calcitonin gene-related peptide-like immunostaining and receptor binding sites. J Pharmacol Exp Ther. 1995, 273:887-94.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1139\/y95-156","article-title":"Alteration of calcitonin gene related peptide and its receptor binding sites during the development of tolerance to mu and delta opioids","volume":"73","author":"M\u00e9nard DP","year":"1995","unstructured":"M\u00e9nard DP, van Rossum D, Kar S, Quirion R. Alteration of calcitonin gene related peptide and its receptor binding sites during the development of tolerance to mu and delta opioids. Can J Physiol Pharmacol. 1995, 73:1089-95. 10.1139\/y95-156","journal-title":"Can J Physiol Pharmacol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703655","article-title":"Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists","volume":"131","author":"Powell KJ","year":"2000","unstructured":"Powell KJ, Ma W, Sutak M, Doods H, Quirion R, Jhamandas K. Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists. Br J Pharmacol. 2000, 131:875-84. 10.1038\/sj.bjp.0703655","journal-title":"Br J Pharmacol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/s0306-4522(00)00226-8","article-title":"Morphine treatment induced calcitonin gene-related peptide and substance P increases in cultured dorsal root ganglion neurons","volume":"99","author":"Ma W","year":"2000","unstructured":"Ma W, Zheng WH, Kar S, Quirion R. Morphine treatment induced calcitonin gene-related peptide and substance P increases in cultured dorsal root ganglion neurons. Neuroscience. 2000, 99:529-39. 10.1016\/s0306-4522(00)00226-8","journal-title":"Neuroscience"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/s0306-4522(02)00452-9","article-title":"Expression of calcitonin gene-related peptide, substance P and protein kinase C in cultured dorsal root ganglion neurons following chronic exposure to mu, delta and kappa opiates","volume":"115","author":"Belanger S","year":"2002","unstructured":"Belanger S, Ma W, Chabot JG, Quirion R. Expression of calcitonin gene-related peptide, substance P and protein kinase C in cultured dorsal root ganglion neurons following chronic exposure to mu, delta and kappa opiates. Neuroscience. 2002, 115:441-53. 10.1016\/s0306-4522(02)00452-9","journal-title":"Neuroscience"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1046\/j.0953-816x.2001.01731.x","article-title":"Chronic morphine exposure increases the phosphorylation of MAP kinases and the transcription factor CREB in dorsal root ganglion neurons: an in vitro and in vivo study","volume":"14","author":"Ma W","year":"2001","unstructured":"Ma W, Zheng WH, Powell K, Jhamandas K, Quirion R. Chronic morphine exposure increases the phosphorylation of MAP kinases and the transcription factor CREB in dorsal root ganglion neurons: an in vitro and in vivo study. Eur J Neurosci. 2001, 14:1091-104. 10.1046\/j.0953-816x.2001.01731.x","journal-title":"Eur J Neurosci"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1177\/0018578718797295","article-title":"Erenumab-aooe","volume":"53","author":"Stoker K","year":"2018","unstructured":"Stoker K, Baker DE. Erenumab-aooe. Hosp Pharm. 2018, 53:363-8. 10.1177\/0018578718797295","journal-title":"Hosp Pharm"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0944-0","article-title":"Erenumab: first global approval","volume":"78","author":"Markham A","year":"2018","unstructured":"Markham A. Erenumab: first global approval. Drugs. 2018, 78:1157-61. 10.1007\/s40265-018-0944-0","journal-title":"Drugs"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01300-4","article-title":"Eptinezumab: first approval","volume":"80","author":"Dhillon S","year":"2020","unstructured":"Dhillon S. Eptinezumab: first approval. Drugs. 2020, 80:733-9. 10.1007\/s40265-020-01300-4","journal-title":"Drugs"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1002-7","article-title":"Galcanezumab: first global approval","volume":"78","author":"Lamb YN","year":"2018","unstructured":"Lamb YN. Galcanezumab: first global approval. Drugs. 2018, 78:1769-75. 10.1007\/s40265-018-1002-7","journal-title":"Drugs"},{"key":"ref50","article-title":"Utilizing CGRP antagonists for non-migraine indications","volume":"21","author":"Limerick G","year":"2021","unstructured":"Limerick G, Doshi T. Utilizing CGRP antagonists for non-migraine indications. Pract Pain Manag. 2021, 21:1-5.","journal-title":"Pract Pain Manag"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2016.02.012","article-title":"Clinical study of cerebrospinal fluid neuropeptides in patients with primary trigeminal neuralgia","volume":"143","author":"Qin ZL","year":"2016","unstructured":"Qin ZL, Yang LQ, Li N, et al.. Clinical study of cerebrospinal fluid neuropeptides in patients with primary trigeminal neuralgia. Clin Neurol Neurosurg. 2016, 143:111-5. 10.1016\/j.clineuro.2016.02.012","journal-title":"Clin Neurol Neurosurg"},{"key":"ref52","unstructured":"Trial for Treatment Refractory Trigeminal Neuralgia. (2019). Accessed. December 18, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03941834."},{"key":"ref53","unstructured":"Efficacy and Tolerability of Erenumab in Patients With Trigeminal Neuralgia. (2019). Accessed. December 18, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04054024."},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v6.i3.432","article-title":"Diabetic neuropathic pain: physiopathology and treatment","volume":"6","author":"Schreiber AK","year":"2015","unstructured":"Schreiber AK, Nones CF, Reis RC, Chichorro JG, Cunha JM. Diabetic neuropathic pain: physiopathology and treatment. World J Diabetes. 2015, 6:432-44. 10.4239\/wjd.v6.i3.432","journal-title":"World J Diabetes"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.6b06104","article-title":"Analgesic microneedle patch for neuropathic pain therapy","volume":"11","author":"Xie X","year":"2017","unstructured":"Xie X, Pascual C, Lieu C, et al.. Analgesic microneedle patch for neuropathic pain therapy. ACS Nano. 2017, 11:395-406. 10.1021\/acsnano.6b06104","journal-title":"ACS Nano"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2017.00174","article-title":"Pathophysiology of chemotherapy-induced peripheral neuropathy","volume":"10","author":"Starobova H","year":"2017","unstructured":"Starobova H, Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2017, 10:174. 10.3389\/fnmol.2017.00174","journal-title":"Front Mol Neurosci"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2021.104981","article-title":"Attenuation of nociceptive and paclitaxel-induced neuropathic pain by targeting inflammatory, CGRP and substance P signaling using 3-Hydroxyflavone","volume":"144","author":"Ullah R","year":"2021","unstructured":"Ullah R, Ali G, Subhan F, et al.. Attenuation of nociceptive and paclitaxel-induced neuropathic pain by targeting inflammatory, CGRP and substance P signaling using 3-Hydroxyflavone. Neurochem Int. 2021, 144:104981. 10.1016\/j.neuint.2021.104981","journal-title":"Neurochem Int"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1001\/jama.257.20.2782","article-title":"Fibromyalgia syndrome. An emerging but controversial condition","volume":"257","author":"Goldenberg DL","year":"1987","unstructured":"Goldenberg DL. Fibromyalgia syndrome. An emerging but controversial condition. JAMA. 1987, 257:2782-7. 10.1001\/jama.257.20.2782","journal-title":"JAMA"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3266","article-title":"Fibromyalgia: a clinical review","volume":"311","author":"Clauw DJ","year":"2014","unstructured":"Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014, 311:1547-55. 10.1001\/jama.2014.3266","journal-title":"JAMA"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2016.06.006","article-title":"Neurobiology of fibromyalgia and chronic widespread pain","volume":"338","author":"Sluka KA","year":"2016","unstructured":"Sluka KA, Clauw DJ. Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience. 2016, 338:114-29. 10.1016\/j.neuroscience.2016.06.006","journal-title":"Neuroscience"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/135553-a-pharmacological-review-of-calcitonin-gene-related-peptide-biologics-and-future-use-for-chronic-pain","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:52:18Z","timestamp":1707508338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/135553-a-pharmacological-review-of-calcitonin-gene-related-peptide-biologics-and-future-use-for-chronic-pain"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":60,"URL":"https:\/\/doi.org\/10.7759\/cureus.35109","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,17]]}}}